Bruker (NASDAQ:BRKR) Rating Increased to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Bruker (NASDAQ:BRKR) from a strong sell rating to a strong-buy rating in a report released on Monday morning,Zacks reports.

BRKR has been the topic of a number of other research reports. Wolfe Research initiated coverage on Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their target price on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Stifel Nicolaus set a $50.00 price target on shares of Bruker in a research report on Wednesday, August 5th. Finally, Citigroup reduced their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bruker presently has an average rating of “Moderate Buy” and a consensus price target of $57.00.

Bruker Stock Down 2.5%

Shares of NASDAQ:BRKR opened at $59.67 on Monday. Bruker has a 52-week low of $30.09 and a 52-week high of $65.30. The company has a market capitalization of $9.09 billion, a price-to-earnings ratio of -85.24, a price-to-earnings-growth ratio of 1.87 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The company has a 50 day moving average of $58.27 and a two-hundred day moving average of $50.44.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm had revenue of $838.50 million for the quarter, compared to analysts’ expectations of $853.57 million. During the same period in the prior year, the company posted $0.32 earnings per share. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts forecast that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. The ex-dividend date is Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is presently -28.57%.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the sale, the vice president directly owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bruker

Several large investors have recently added to or reduced their stakes in BRKR. Sequoia Financial Advisors LLC acquired a new stake in shares of Bruker during the 2nd quarter valued at about $250,000. Tidal Investments LLC grew its stake in shares of Bruker by 180.4% during the second quarter. Tidal Investments LLC now owns 29,092 shares of the medical research company’s stock valued at $1,751,000 after purchasing an additional 18,715 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Bruker in the second quarter valued at approximately $344,000. Engineers Gate Manager LP raised its position in Bruker by 141.8% in the 2nd quarter. Engineers Gate Manager LP now owns 56,825 shares of the medical research company’s stock worth $3,420,000 after purchasing an additional 33,329 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in Bruker during the 2nd quarter worth $445,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.